WEBINAR #1

Co. Snapshot | 2019 Recap | 2020 and Beyond | Reg A+ | Q&A

Corporate, Financing & IPO

Q: When do you anticipate EHP's IPO?
A: Unfortunately, due to SEC regulations, we are unable to comment if or when the Company will IPO, however, it is definitely our intent to create liquidity for your shares and that can happen through a public listing or acquisition.

Q: Will the capital on hand allow EHP to get through phase 2A & 2B?
A: No, clinical trials are very costly and since EHP is planning multiple Phase 2 studies in two disease indications over the next few years, we are currently continuing our Regulation A investment opportunity for individual investors for a few more months and are planning an institutional round to bring in investors who can support an IPO.

Commercialization

Q: At what point of success in clinical trials would EHP become known and be considered an acquisition target by big Pharma?
A: Typically, companies gain the interest of big pharma with clear, positive Phase 2 efficacy data.

Q: Once Phase 2 studies are over successfully in the US, how many years for EHP-101 to be released for open distribution to patients for treatment?
A: Typically, it takes 3-5 years after Phase 2 for a new drug to get approved by the regulatory authorities, become commercialized and available to patients where the drug is approved. This varies with the type of drug (for example, Orphan Drugs can move more quickly than certain other types of drugs) and the disease indication (for example, many chronic diseases require clinical studies that go on for years, whereas acute diseases may need studies that only require weeks or months).

Q: How will EHP scale up production of the EHP 101 molecule for market?
A: EHP-101 is formulated through a synthetic process, therefore scalability is not an issue as we have the ability to produce as much of the drug as needed in the manufacturing process.

Q: How far away are you from commercial sales?
A: The typical timeline for commercial sales would be 3-5 years after the new drug candidate achieves successful Phase 2 efficacy data. This timeline would vary depending on rather EHP-101 or any investigational new drug receives orphan drug designation or breakthrough therapy designation, which is granted to therapies that serve a significant unmet medical need and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies. Either one of these designations, this could shorten the timeframe to commercialization.

EHP-101

Q: Is it because of the orphan designation that you are planning for the phase 2 clinical trial for Scleroderma prior to Multiple Sclerosis?
A: Our initial Phase 2 clinical study of EHP-101 will be in patients with systemic sclerosis (a severe, deadly form of scleroderma with no current cure), which represents the quickest path to key value-driving efficacy data, as well the requirement for less up-front capital to initiate the trial.

With the initiation of the Phase 2 clinical study in SSc currently underway, we expect to start seeing important efficacy data by the end of 2020 which, if positive, will help support the mechanism of action of EHP-101, which could thereby support the potential for efficacy in other diseases, including fibrotic diseases and even demyelinating diseases.

Q: For FDA Ok for the EHP101, is this 501k?
A: No, a 510(k) is used for medical devices, not pharmaceuticals.

Q: When will Phase II for EHP-101 start? Also, how long was the treatment regimen on the mice until positive results were discovered regarding the myelinization?
A: Our initial Phase 2 clinical study of EHP-101 in patients with systemic sclerosis is currently underway. The studies in mice vary in duration depending on the study. In some models, the mice were treated for 3-4 weeks with very good results regarding demyelination. In other studies, the animals were treated for 6 weeks and some for 12 week or more – all showing excellent results on remyelination.

Participation in Clinical Trials

Q: How do potential patients learn about volunteering for this (Phase 2 of EHP-101 in MS and/or SSc) study?

A: At this time we are not recruiting patients, once the study is open for recruitment we will update the clinicaltrials.gov website. We have received approval to begin the study and expect to start enrolling patients within the next couple of months, so we are on track. Please note that our first research centers for this Phase 2 clinical trial of EHP-101 for the treatment of systemic sclerosis will be located in Australia and we will expand into the US later in the year.

You may find the eligibility criteria on the clinicaltrials.gov website by clicking here, however you will need to speak directly with your doctor to determine eligibility. Additionally, you or your doctor may contact the study research staff using the contacts provided on the clinicaltrials.gov website to learn more information.